Caption Management’s Oric Pharmaceuticals ORIC Stock Holding History

Caption Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-60,000	Closed	-$720K	–	1947
2025 Q3	$720K	Buy	+60,000	New	+$631K	0.01%	1210
2024 Q1	–	Sell	-200,000	Closed	-$1.84M	–	1558
2023 Q4	$1.84M	Buy	+200,000	New	+$1.45M	0.02%	643
2023 Q3	–	Sell	-50,000	Closed	-$388K	–	1463
2023 Q2	$388K	Buy	+50,000	New	+$284K	0.01%	859

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's ORIC Position: Q4 2025 in Review

Caption Management sold out of Oric Pharmaceuticals (ORIC) in Q4 2025, closing a stake of 49,389 shares — an estimated $593K sold.

Caption Management first reported a position in ORIC in Q2 2023 and held it in 4 quarters. The position peaked at $876K in Q4 2023. 164 funds tracked by Wall St. Rank hold ORIC as of Q4 2025.

Caption Management reported no remaining Oric Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Caption Management sold 49,389 Oric Pharmaceuticals shares in Q4 2025, an estimated $593K.
Caption Management first reported a position in Oric Pharmaceuticals in Q2 2023 and held it in 4 quarters.
Caption Management's Oric Pharmaceuticals position peaked at $876K in Q4 2023.
164 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.